Henry L.Y. Chan, MD; E. Jenny Heathcote, MD; Patrick Marcellin, MD; Ching-Lung Lai, MD; Mong Cho, MD; Young M. Moon, MD; You-Chen Chao, MD; Robert P. Myers, MD; Gerald Y. Minuk, MD; Lennox Jeffers, MD; William Sievert, MD; Natalie Bzowej, MD, PhD; George Harb, MD; Ralf Kaiser, PhD; Xin-Jian Qiao, ScD; Nathaniel A. Brown, MD; and the 018 Study Group
Chan HL, Heathcote EJ, Marcellin P, Lai C, Cho M, Moon YM, et al. Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis with Telbivudine or Adefovir: A Randomized Trial. Ann Intern Med. 2007;147:745-754. doi: 10.7326/0003-4819-147-11-200712040-00183
Download citation file:
Published: Ann Intern Med. 2007;147(11):745-754.
Optimal regimens for suppressing virus in chronic hepatitis B infection are unclear.
In this 52-week open label trial, 135 adults with hepatitis B e antigen–positive chronic hepatitis B were randomly assigned to telbuvidine, adefovir, or adefovir for 24 weeks followed by telbivudine for 28 weeks. The telbivudine and the adefovir-to-telbivudine groups experienced similar reductions in viral levels that were greater than those in the adefovir group.
The small trial did not establish long-term drug resistance or effects on clinical outcomes.
Telbivudine and switching from adefovir to telbivudine suppressed viral levels more than adefovir in adults with chronic hepatitis B.
Primary exclusion criteria are listed; some patients met more than 1 exclusion criterion. One patient assigned to adefovir withdrew before initiation of treatment; thus, the intention-to-treat sample was 135 patients, of whom 45, 44, and 46 were assigned to receive telbivudine, adefovir, or adefovir for 24 weeks and then telbivudine for the remaining 28 weeks, respectively. One adefovir recipient withdrew before the week-24 analysis; 1 additional adefovir recipient and 2 telbivudine recipients withdrew before the week-52 analysis. ALT = alanine aminotransferase; HBeAg = hepatitis B e antigen; HBV = hepatitis B virus.
Top. Mean serum HBV DNA levels. Bottom. Proportion of patients with hepatitis B e antigen (HBeAg) seroconversion. ADV = adefovir; ADV/LdT = adefovir to telbivudine; LdT = telbivudine.
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Other Audio Options: Download MP3
Gastroenterology/Hepatology, Infectious Disease, Liver Disease.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only